

DICON Weekly Digest: 12/21/2020

Prepared by: Esther Baker, MSN, RN, CIC, Linda Crane, BSMT (ASCP) SM, CIC, Lynn Cromer, MPH, RN, MT, CPH, CIC, Polly Padgette, BSN, RN, CIC, FAPIC, Kathy Crawford, BSBA-HCM, RN, CIC, Linda Roach, BSMT, CCHM, CIC, Brittain Wood, BSN, RN, CRCST, CIC

COVID-19 Tracker & Statistics:

Duke University Dashboard (updated weekly) [here](#).

UNC Health Dashboard (updated daily) [here](#).

NC DPH Dashboard (updated daily) [here](#).

SC DPH Dashboard (updated daily) [here](#).

GA DPH Dashboard (updated weekly) [here](#).

VA DPH Dashboard (updated daily) [here](#).

WV DPH Dashboard (updated daily) [here](#).

FL DPH Dashboard (updated daily) [here](#).

Johns Hopkins Global Dashboard (updated daily) [here](#).

COVID-19 Guidance & Resources:

DICON website [here](#).

CDC website [here](#).

COVID-19 Vaccine Tracker:

NYT Vaccine Tracker [here](#).

COVID-19 Vaccine News:

- **Johnson & Johnson** (adenovirus vector vaccine, initially studied as 1 dose)
 - Pending FDA approval (review scheduled for February 26, 2021).
- **Astra Zeneca** (adenovirus vector vaccine, initially studied as 2 doses)
 - Pending FDA approval in US (approved in Europe).
- **Pfizer** (mRNA, 2 doses, administered 21 days apart)
 - [Authorized](#) for emergency use: 12/11/2020.
- **Moderna** (mRNA, 2 doses, administered 28 days apart)
 - [Authorized](#) for emergency use: 12/18/20.

CDC:

- CDC has launched Project Firstline, a series of [resources](#) to assist frontline healthcare workers understand and confidently apply the infection control principles and protocols necessary to protect themselves, their facility, their family, and their community.
- [Vaccine Considerations for People with Disabilities.](#)
- [Information for School Nurses and Health Professionals.](#)
- [Toolkit for Correctional and Detention Facilities.](#)

FDA:

- The FDA is alerting health care professionals and compounders of [potential risks](#) associated with compounding remdesivir drug products. The FDA cautions against compounding remdesivir drug products. The agency recommends health care providers utilize the FDA-approved drug for patients who are prescribed remdesivir.

- On Feb. 4, the FDA revised the [Letter of Authorization](#) for COVID-19 convalescent plasma to limit the authorization to the use of high titer COVID-19 convalescent plasma for the treatment of hospitalized patients with COVID-19 early in the disease course and to those hospitalized patients who have impaired humoral immunity and cannot produce an adequate antibody response.

OSHA:

- OSHA released “[Protecting Workers: Guidance on Mitigating and Preventing the Spread of COVID-19 in the Workplace](#),” guidance for employers to keep workers safe from COVID-19 exposure. The guidance is not a new standard or regulation, but contains recommendations as well as descriptions of existing mandatory safety and health standards.

TJC:

- A whitepaper, co-authored by Deloitte and Joint Commission Resources, titled “[COVID-19 Lessons Learned: A Resource for Recovery](#)” describes observed best practices adopted by organizations throughout the COVID-19 response.

Interesting Literature for Infection Prevention:

- Our DUKE-UNC EPICENTER Colleagues:
 - [Single-dose vaccination effective for healthcare workers with prior SARS-CoV-2 infection.](#)
- [National Trends in the US Public’s Likelihood of Getting a COVID-19 vaccine.](#)
- [Vaccine Distribution- Equity Left Behind.](#)
- [SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants.](#)
- [COVID-19 symptoms and SARS-CoV-2 antibody positivity in a large survey of first responders and healthcare personnel, May-July 2020.](#)
- [Sexual Orientation Disparities in Risk Factors for Adverse COVID-19–Related Outcomes, by Race/Ethnicity — Behavioral Risk Factor Surveillance System, United States, 2017–2019.](#)
- [Demographic Characteristics of Persons Vaccinated During the First Month of the COVID-19 Vaccination Program — United States, December 14, 2020–January 14, 2021.](#)
- [Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program — United States, December 2020–January 2021.](#)
- [Disentangling the COVID-19 Health Disparities in African Americans: Biological, Environmental and Social Factors.](#)
- [Bacterial superinfections among persons with coronavirus disease 2019:A comprehensive review of data from postmortem studies.](#)
- [Clinical and laboratory follow-up after hospitalization for COVID-19 at an Italian tertiary care center.](#)
- [Establishment of Monoclonal Antibody Standards for Quantitative Serological Diagnosis of SARS-CoV-2 in Low Incidence Settings.](#)
- [Prolonged Symptoms after COVID-19 Infection in Outpatients.](#)
- [Nasopharyngeal Panbio COVID-19 antigen performed at point-of-care has a high sensitivity in symptomatic and asymptomatic patients with higher risk for transmission and older age.](#)
- [Transmission routes of SARS-CoV-2 among healthcare workers of a French university hospital in Paris, France.](#)

- [COVID-19 Testing Results by HIV Status, March-July 2020, Chicago, USA.](#)
- [Comparison all-cause mortality between individuals with COVID-19 and propensity-score-matched individuals without COVID-19 in South Korea.](#)
- [Infectious period of SARS-CoV-2 in 17 nursing home residents — Arkansas, June–August 2020.](#)
- [Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa.](#)
- [Persistent symptoms in hospitalized patients recovering from COVID-19 in Denmark.](#)

Do you have a suggestion for a new FAQ, position statement, or newsletter?

Reach out [here](#) or discuss with your DICON IP liaison.